Benzhydrol-pyrazole derivatives having kinase inhibitory activity and uses thereof

1. A compound having the formula:

or a stereoisomer or pharmaceutically acceptable salt thereof,

wherein

n is an integer from 0 to 4, and each R 1 is, independently, optionally substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl, optionally substituted halo-C 1-6 alkyl, optionally substituted C 1-6 alkoxy, optionally substituted C 2-6 alkenyloxy, optionally substituted C 2-6 alkynyloxy, optionally substituted halo-C 1-6 alkoxy, optionally substituted C 1-6 alkoxy-C 1-6 alkyl, optionally substituted C 1-7 acyl, optionally substituted C 1-7 acylamino, optionally substituted C 1-7 acyloxy, optionally substituted C 6-10 aryl, optionally substituted C 1-6 alk-C 6-10 aryl, optionally substituted amino, halo, cyano, nitro, hydroxy, or carboxyl;

Ar is optionally substituted C 6-10 aryl or optionally substituted C 1-12 heteroaryl;

R 2 is independently, H, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl, optionally substituted halo-C 1-6 alkyl, optionally substituted C 1-6 alkoxy, optionally substituted C 2-6 alkenyloxy, optionally substituted C 2-6 alkynyloxy, optionally substituted halo-C 1-6 alkoxy, optionally substituted C 1-7 acyl, optionally substituted amino, halo, cyano, nitro, hydroxy, carboxyl, or an N-protecting group;

Y is —CY 1 Y 2 —NY N1 -, wherein each Y N1 is, independently, H, optionally substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl, or an N-protecting group; and wherein each Y 1 and Y 2 is, independently, H, optionally substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, or optionally substituted C 2-6 alkynyl; or wherein the combination of Y 1 and Y 2 can together form oxo or optionally substituted C 1-7 spirocyclyl;

Z is H, optionally substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl, optionally substituted halo-C 1-6 alkyl, optionally substituted C 1-6 alkoxy, optionally substituted C 2-6 alkenyloxy, optionally substituted C 2-6 alkynyloxy, optionally substituted halo-C 1-6 alkoxy, optionally substituted C 1-6 alkoxy-C 1-6 alkyl, optionally substituted C 1-7 acyl, optionally substituted C 1-7 acylamino, optionally substituted C 1-7 acyloxy, optionally substituted C 6-10 aryl, optionally substituted C 1-6 alk-C 6-10 aryl, optionally substituted amino, halo, cyano, nitro, hydroxy, or carboxyl;

L is optionally substituted C 1-10 alkylene, optionally substituted C 1-10 heteroalkylene, —NR L3 —C(O)—, —C(O)—NR L3 —, —NR L3 —CR L1 R L2 —, —CR L1 R L2 NR L3 —, or a bond, wherein each R L1 and R L2 is, independently, H, optionally substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl; or wherein the combination of R L1 and R L2 can together form oxo or optionally substituted C 1-7 spirocyclyl; and wherein each R L3 is, independently, H, optionally substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl, or an N-protecting group; and

X is optionally substituted C 1-6 alkyl, optionally substituted C 3-8 cycloalkyl, optionally substituted C 6-10 aryl, or optionally substituted C 1-12 heterocyclyl.

2. The compound of claim 1 , wherein

n is an integer from 0 to 2;

Ar is optionally substituted C 6-10 aryl or optionally substituted C 1-12 heteroaryl;

each Y 1 and Y 2 is, independently, H or optionally substituted C 1-6 alkyl;

Z is H, optionally substituted C 1-6 alkyl, optionally substituted halo-C 1-6 alkyl, or halo;

L is —NH—C(O)—, —C(O)—NH—, —NH—CR L1 R L2 —, —CR L1 R L2 —NH—, or a bond, wherein each R L1 and R L2 is, independently, H or optionally substituted C 1-6 alkyl; and

X is optionally substituted C 1-6 alkyl, optionally substituted C 6-10 aryl, or optionally substituted C 1-12 heterocyclyl.

3. The compound of claim 1 , wherein said compound has the formula:

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 , wherein said compound has the formula:

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 , wherein said compound has the formula:

or a stereoisomer or pharmaceutically acceptable salt thereof.

6. The compound of claim 1 , wherein said compound has the formula:

or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1 , wherein n is 0.

8. The compound of claim 1 , wherein Ar has the formula:

and

wherein the combination of R a and R b or the combination of R b and R c can together form optionally substituted C 6-10 aryl or optionally substituted C 1-12 heterocyclyl.

9. The compound of claim 1 , wherein Ar is optionally substituted C 1-12 heteroaryl.

10. The compound of claim 1 , wherein Ar is selected from the group consisting of optionally substituted phenyl, optionally substituted pyridyl, optionally substituted pyrimidinyl, optionally substituted pyrazinyl, optionally substituted pyridazinyl, optionally substituted naphthyl, optionally substituted indenyl, optionally substituted anthryl, optionally substituted phenanthryl, optionally substituted quinolyl, optionally substituted isoquinolyl, optionally substituted quinoxalinyl, optionally substituted quinazolinyl, optionally substituted cinnolinyl, optionally substituted phthalazinyl, and optionally substituted quinolizinyl.

11. The compound of claim 10 , wherein Ar is optionally substituted phenyl, optionally substituted naphthyl, optionally substituted quinolyl, or optionally substituted isoquinolyl.

12. The compound of claim 11 , wherein Ar is substituted with C 1-6 alkyl, halo-C 1-6 alkyl, C 1-6 alkoxy, halo-C 1-6 alkoxy, or halo.

13. The compound of claim 1 , wherein each of Y 1 , Y 2 , and Z, if present, is, independently, H or optionally substituted C 1-6 alkyl, or wherein the combination of Y 1 and Y 2 can together form oxo or spirocyclopropyl.

14. The compound of claim 1 , wherein X is optionally substituted C 6-10 aryl or optionally substituted C 1-12 heteroaryl.

15. The compound of claim 14 , wherein X is optionally substituted phenyl.

16. The compound of claim 15 , wherein X is unsubstituted phenyl or phenyl substituted with a substituent selected from the group consisting of C 1-6 alkyl, halo-C 1-6 alkyl, C 1-6 alkoxy, halo-C 1-6 alkoxy, halo, C 1-12 heterocyclyl, —(CH 2 ) m —CO 2 R X1 , —(CH 2 ) m —C(O)—NR X1 R X2 , and —(CH 2 ) m —NR X1 —C(O)—R X2 , wherein m is an integer from 0 to 4 and each R X1 and R X2 is, independently, H or optionally substituted C 1-6 alkyl.

17. The compound of claim 14 , wherein X is selected from the group consisting of optionally substituted quinoxalinyl, optionally substituted quinazolinyl, optionally substituted cinnolinyl, optionally substituted phthalazinyl, optionally substituted quinolyl, optionally substituted isoquinolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted benzothiazolyl, optionally substituted benzothiadiazolyl, optionally substituted indolyl, optionally substituted indazolyl, optionally substituted benzofuranyl, optionally substituted isobenzofuranyl, and optionally substituted benzothienyl.

18. A compound having the formula:

or a stereoisomer or pharmaceutically acceptable salt thereof.

19. A pharmaceutical composition comprising the compound of claim 1 , or a stereoisomer, pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

20. A method of inhibiting Bruton's tyrosine kinase (BTK) in a subject in need thereof, wherein said method comprises administering an effective amount of the compound of claim 1 , or a stereoisomer, pharmaceutically acceptable salt, or pharmaceutical composition thereof to said subject.

21. A method of treating lymphoma in a subject in need thereof by inhibiting Bruton's tyrosine kinase (BTK), said method comprising administering an effective amount of a compound of claim 1 , or a stereoisomer, pharmaceutically acceptable salt, or pharmaceutical composition thereof, to said subject.

22. The method of claim 21 , wherein said lymphoma is non-Hodgkin lymphoma, B-cell lymphoma, or small lymphocytic lymphoma.